Topical thrombin preparations and their use in cardiac surgery

References

• Dacey LJ, Munoz JJ, Baribeau YR, et al. Re-exporation for hemorrhage following coronary artery bypass grafting. Arch Surg. 1998; 133: 442–447.
   PubMed Web of Science ®Google Scholar
• Hall TS, Sines JC, Spotnitz AJ. Hemorrhage related re-exploration following open heart surgery: the impact of pre-operative and postoperative coagulation testing. Cardiovasc Surg. 2002;10:146–153.
   Google Scholar
• Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Re-exploration for bleeding is a risk factor for adverse outcomes after cardiac operation. J Thoracic Cardiovasc Surg. 1996;111:1037–1046.
   PubMed Web of Science ®Google Scholar
• Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg. 1995;59:664–667.
   PubMed Web of Science ®Google Scholar
• Karkouti K, Yau TM, Rinzi S, et al. Determinants of complications with recombinant factor Vila for refractory blood loss in cardiac surgery. Can JAnesth. 2006;53:802–809.
   Web of Science ®Google Scholar
• Despotis G, Avidan M, Lublin DM. Off-label use of recombinant factor Vila concentrates after cardiac surgery. Ann Thorac Surg. 2005;80:3–5.
   PubMed Web of Science ®Google Scholar
• Whitlock R, Crowther MA, Ng HJ. Bleeding in cardiac surgery: its prevention and treatments – an evidence-based review. Crit Care Clin. 2005;21:589–610.
   Web of Science ®Google Scholar
• Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608–1616.
   PubMed Web of Science ®Google Scholar
• Engoren MC, Habib RH, Zacharis A, Schwann TA, Riordan CJ, Druham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180–1186.
   PubMed Web of Science ®Google Scholar
• Moore FA, Moore EE, Sanaia A. Blood transfusion. An independent risk factor for post-injury multiple organ failure. Arch Surg. 1997;142:85–93.
   Google Scholar
• Taylor RW, Manganaro L, O’Brien J, Trottier SJ, Parker N, Veremakis C. impact of allogenic packed red blood cell transfusion or nosocomial infection rates in the critically ill patient. Crit Care Med. 2002;30: 2389–2391.
   Web of Science ®Google Scholar
• Vincent JL, Baron JF, Reinhert K, et al. Anemia and blood transfusions in critically ill patients. JAMA. 2002;288:1499–1507.
   PubMed Web of Science ®Google Scholar
• Blajchman MA, VanVakas EC. The continuing risk of transfusion and transmitted infections. N Engl J Med. 2006;355:1303–1305.
   PubMed Web of Science ®Google Scholar
• Fransen E, Maessen J, Dentener M, Seuden N, Buurman W. impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116:1233–1239.
   PubMed Web of Science ®Google Scholar
• Levy JH. Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas. Hematol Oncol Clin North Am. 2007;21:89–101.
   Web of Science ®Google Scholar
• Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost. 2009;101:15–24.
   Google Scholar
• Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006;32(Suppl 1):98–110.
   PubMed Web of Science ®Google Scholar
• Diesen DL, Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular. 2008;16(Suppl 1): S29–S36.
   PubMed Web of Science ®Google Scholar
• Lew WK, Weaver FA. Clinical use of topical thrombin as a surgical hemostat. Biologics. 2008;2:593–599.
   PubMedGoogle Scholar
• Cheng CM, Meyer-Massetti C, Kayser SR. A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther 2009;31:32–41.
   PubMed Web of Science ®Google Scholar
• Dagi TF. The management of postoperative bleeding. Surg Clin North Am. 2005;85:1191–1213.
   PubMed Web of Science ®Google Scholar
• Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion. 2008;48:1502–1516.
   PubMed Web of Science ®Google Scholar
• Rothenberg DM, Moy JN. Anaphylactic reaction to topical bovine thrombin. Anesthesiology. 1993;78:779–782.
   PubMed Web of Science ®Google Scholar
• Pope M, Johnston KW. Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. J Vasc Surg. 2000;32:190–191.
   Web of Science ®Google Scholar
• Wai Y, Tsui, Peng Z, Richardson R, Oreopoulos D, Tarlo SM. Anaphylaxis from topical bovine thrombin (Thrombostat®) during hemodialysis and evaluation of sensitization among a dialysis population. Clin Exp Allergy 2003;33:1730–1734.
   PubMed Web of Science ®Google Scholar
• Sands JJ, Nudo SA, Ashford RG, Moore KD, Ortel TL. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis. 2000;35:796–801.
   Web of Science ®Google Scholar
• Fastenau DR, Hormuth DA, Mcintyre JA. Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin. Transplant Proc. 1998;31:141–142.
   Web of Science ®Google Scholar
• Su Z, izumi T, Thames EH, Lawson JH, Ortel TL. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med. 2002;139:349–356.
   PubMed Web of Science ®Google Scholar
• Flaherty MJ, Henderson R, Wener MH. iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med. 1989;111:631–634.
   PubMed Web of Science ®Google Scholar
• Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990;76:2011–2016.
   PubMed Web of Science ®Google Scholar
• Muntean W, Zenz W, Finding K. Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue. Wien Klin Wochenschr. 1992;104:101–104.
   Web of Science ®Google Scholar
• Rapaport Si, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992;97: 84–91.
   PubMed Web of Science ®Google Scholar
• Banninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol. 1993;85:528–532.
   PubMed Web of Science ®Google Scholar
• Berruyer M, Amiral J, Ffrench P, et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg. 1993; 105:892–897.
   PubMed Web of Science ®Google Scholar
• Cmolik BL, Spero JA, Magovern GJ, Clark RE. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg. 1993;105:222–228.
   PubMed Web of Science ®Google Scholar
• Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients: Report of three cases. J Neurosurg. 1993;78:817–820.
   PubMed Web of Science ®Google Scholar
• Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol. 1994;16:249–254.
   PubMedGoogle Scholar
• Muntean W, Zenz W, Finding K, Zobel G, Beitzke A. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr. 1994;83:84–87.
   PubMed Web of Science ®Google Scholar
• Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994;45:128–135.
   PubMed Web of Science ®Google Scholar
• La Spada AR, Skålhegg BS, Henderson R, Schmer G, Pierce R, Chandler W. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med. 1995;333:494–497.
   PubMed Web of Science ®Google Scholar
• Chouhan VD, De La Cadena RA, Nagaswami C, Weisel JW, Kajani M, Rao AK. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation protein C activation and platelet function. Thromb Haemost. 1997;77:343–349.
   PubMed Web of Science ®Google Scholar
• Christie RJ, Carrington L, Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery. 1997;121: 708–710.
   PubMed Web of Science ®Google Scholar
• Israels SJ, Leaker MT. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin. J Pediatr. 1997;131:480–483.
   Web of Science ®Google Scholar
• Muntean W, Zenz W, Edlinger G, Beitzke A. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb Haemost. 1997;77:1223.
   Web of Science ®Google Scholar
• Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol. 1997;19:226–231.
   PubMed Web of Science ®Google Scholar
• Dorion RP, Hamati HF, Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med. 1998;122:887–894.
   PubMed Web of Science ®Google Scholar
• Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg. 2000; 15:378–382.
   PubMed Web of Science ®Google Scholar
• Zumberg MS, Waples JM, Kao KJ, Lottenberg R. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol. 2000;64:59–63.
   PubMed Web of Science ®Google Scholar
• Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy: A case report. J Reprod Med. 2001;46:909–912.
   PubMed Web of Science ®Google Scholar
• Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233:88–96.
   PubMed Web of Science ®Google Scholar
• Pavlovich CP, Battiwalla M, Rick ME, Walther MM. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. J Urol. 2001;165:1617.
   Web of Science ®Google Scholar
• Neschis DG, Heyman MR, Cheanvechai V, Benjamin ME, Flinn WR. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. JVasc Surg. 2002;35:400–402.
   Web of Science ®Google Scholar
• Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002;42:18–26.
   PubMed Web of Science ®Google Scholar
• Winterbottom N, Kuo JM, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: A prospective study of 309 patients. JApplRes. 2002;2:20–29.
   Google Scholar
• Poynton AR, Nelson MC, McCance SE, Levine RL, O’Leary PF. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine. 2003;28: E221-E223.
   Web of Science ®Google Scholar
• Sarfati MR, DiLorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004;18:349–351.
   PubMed Web of Science ®Google Scholar
• Kapoor A, Cortese Hassett AL, Bontempo FA. Lack of response bleeding acquired from factor V inhibitor to recombinant human factor VIIa concentrate. Blood. 2005;106:Abstract 4099.
   Google Scholar
• Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am J Med. 2005;118:805.
   Web of Science ®Google Scholar
• Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005;79:1037–1038.
   PubMed Web of Science ®Google Scholar
• Shah AK, Moreno-Aspitia A. Acquired factor V inhibitor and single exposure to autologous growth factor. Thromb Res. 2005;116:87–89.
   Web of Science ®Google Scholar
• Crow SS, Sullivan VV, Aysola AE, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg. 2007;83:1547–1549.
   Web of Science ®Google Scholar
• Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer. 2007;49:1025–1029.
   Web of Science ®Google Scholar
• Naoum JJ. Immune-mediated coagulopathy: a case report. Pharmacotherapy. 2009;29(7 pt 2):13S–17S.
   Web of Science ®Google Scholar
• Thrombin-JMI® [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2007.
   Google Scholar
• Evithrom® [package insert]. Somerville, NJ: Johnson & Johnson Wound Management; 2007.
   Google Scholar
• Recothrom® [package insert]. Seattle, WA: ZymoGenetics, Inc.; 2008.
   Google Scholar
• Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008;24:785–794.
   PubMed Web of Science ®Google Scholar
• Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, doubleblind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205:256–265.
   PubMed Web of Science ®Google Scholar
• Weaver FA, Lew W, Granke K, et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg. 2008;47:1266–1273.
   PubMed Web of Science ®Google Scholar
• Singla NK, Ballard JL, Moneta G, Randleman CD, Renkens KL, Alexander WA. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg. 2009;209:68–74.
   Web of Science ®Google Scholar
• Adams GL, Manson RJ, Turner I, Sindra MD, Lawson JH. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am. 2007;21:13–24.
   PubMed Web of Science ®Google Scholar
• Boucher BA, Traub O. Achieving hemostasis in the surgical field. Pharmacotherapy. 2009;29(7 pt 2):2S–7S.
   Web of Science ®Google Scholar
• Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem. 2004;11:2245–2260.
   PubMed Web of Science ®Google Scholar
• Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. JBiomed Mater Res. 2001;58:710–719.
   PubMed Web of Science ®Google Scholar
• Schoenecker JG, Johnson RK, Fields RC, et al. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg. 2003;197:580–590.
   Web of Science ®Google Scholar
• Terrab A, Pawlak D, Spaay P, Hoppensteadt D, Fareed J. Further removal of factor V related antigen from bovine thrombin by utilizing a membranefiltration step. Clin Appl Thromb Hemost. 2008;14:135–140.
   Web of Science ®Google Scholar
• Lomax C, Traub O. Topical thrombins: benefits and risks. Pharmacotherapy. 2009;29(7 pt 2):8S–12S.
   Web of Science ®Google Scholar
• Clark J, Crean S, Reynolds MW. Topical bovine thrombin and adverse events: a review of the literature.. Current Med Res Opin. 2008;24:2071–2087.
   PubMed Web of Science ®Google Scholar
• Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. Br J Surg. 2008;95:1197–1225.
   PubMed Web of Science ®Google Scholar
• CME Zone: Explore the Zone [Internet]. CECity.com, Inc.; 2009. Evaluating the efficacy, immunogenicity, and safety of topical thrombins in surgery; 2009 Jun 1. URL: http://www.cmezone.com. Accessed 2009 Aug 14.
   Google Scholar
• Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1–3 galactose. J Clin Immunol. 2000;20:434–444.
   PubMed Web of Science ®Google Scholar
• Crean SM, Michels SL, Reynolds MW. Exogenous bovine thrombin as a biomarker of exposure and outcome. Expert Rev Mol Diagn. 2008;8:651–661.
   Web of Science ®Google Scholar
• Voils SA. Thrombin products: economic impact of immune- mediated coagulopathies and practical formulary considerations. Pharmacotherapy. 2009;29(7 pt 2):18S–22S.
   Web of Science ®Google Scholar
• The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association. Perioperative blood transfusion and blood conservation in cardiac surgery: clinical practice guideline. Ann Thorac Surg. 2007;83: S27-S86.
   Web of Science ®Google Scholar
• Chediak J, Ashenhurst JB, Garlick I, Desser RK. Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions. Blood. 1980;56:835–841.
   Web of Science ®Google Scholar
• Terrab A, Lawlak D. Validation of a prion and virus purification process in the manufacture of bovine thrombin. J Appl Res. 2007;7:217–226.
   Google Scholar
• DeVeau I, Dabbah R, Sutton S. The USP perspective to minimize the potential risk of TSE infectivity in bovine-derived article used in the manufacture of medical products. Pharmacopeial Forum. 2004; 30:1911–1921.
   Google Scholar
• Bishop PD, Lewis KB, Schultz J, Walker KM. Comparison of recombinant human thrombin and plasma-derived human a-thrombin. Semin ThrombHemost. 2006;32(Suppl 1):86–97.
   Google Scholar
• Horowitz B, Busch M. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion. 2008;48:1739–1753.
   PubMed Web of Science ®Google Scholar
• Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol. 2009;144:14–23.
   PubMed Web of Science ®Google Scholar
• Chapman WC, Lockstadt H, Singla N, Kafie FE, Lawson JH. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost. 2006;4:2083–2085.
   PubMed Web of Science ®Google Scholar
• Recothrom®. In: DRUGDEX® System [Internet database]. Greenwood Village, CO: Thomson Micromedex. Updated periodically.
   Google Scholar
• American Society of Health-System Pharmacists. AHFS drug information. Bethesda, MD: AHFS Inc.; 2008.
   Google Scholar
• Thomson Healthcare Staff. Red Book: Pharmacy’s Fundamental Reference. Montvale, NJ: Thomson PDR; 2009.
   Google Scholar